HER2-positive breast cancer carries more HER2 protein on the tumor surface than normal cells. That protein acts like a stuck accelerator pedal, making the cancer spread faster than most hormone ...

Boehringer Ingelheim’s drug candidate for human epidermal growth factor receptor 2 (HER2)-mutated non-small cell lung cancer (NSCLC) has demonstrated a durable response of more than 14 months ...

Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline. Learn ...

The UK drugs regulator has approved Seagen’s Tukysa as a third-line treatment for HER2-positive breast cancer, shortly after it was given a green light by the European Commission. Tukysa ...

Drugs designed to target HER2-postive breast cancer could also benefit some patients with bile duct cancer, according to results of a patient trial to be presented on Thursday at the 36th EORTC ...

OS Therapies’ HER2-focused immunotherapy prevented patients’ lung cancer from returning in 33% of cases, hitting the primary goal of a phase 2 trial. The therapy, dubbed OST-HER2, uses a HER2 ...

However, targeted drugs that focus on the HER2 protein are often effective treatment options. If HER2-positive breast cancer is detected and treated early, the chance for a cure is possible. [1] ...

An investigational antibody-drug conjugate proved active and safe for patients with previously treated HER2-mutant non-small cell lung cancer (NSCLC), a phase II trial from China showed.

At the moment, there is only one oral anti-HER2 drug on the market, Pfizer's Tukysa (tucatinib), although, that is only approved for HER2-positive breast and colorectal cancers.

The treatment combines a new drug, inavolisib (Itovebi ®), with two older breast cancer drugs, fulvestrant (Faslodex ®) and palbociclib (Ibrance ®). Inavolisib, which targets PIK3CA mutations, appears ...

What’s even more exciting is that this drug also works for people with lower levels of HER2 (called HER2-low cancers), which means it could help even more patients in the future.

If you have early-stage HER2-positive breast cancer, here’s good news: There are more treatment options than ever. They can help you live longer while you enjoy a good quality of life.